283P Treatment outcomes and toxicity of sunitinib in advanced renal cell carcinoma patients

Abstract

Background Between November 2012 and December 2014, 30 patients with histologically confirmed advanced renal cell carcimona (RCC) were treated with sunitinib at Ain Shams Clinical Oncology Department. Medical records were retrospectively reviewed for clinicopathologic characteristics such as age, sex, histology, Eastern Cooperative Oncology Group (ECOG) performance statussites of metastasis, laboratory findings, tumor progression and patient survival. Any Eastern Cooperative OncologyGroup (ECOG) performance status was permitted. Both treatmentschedules were included. Each patient was classified according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring system . Methods:Thirtypatientswereenrolledinthestudy;aged25yearsorolder.Allpatients received oral sunitinib 50 mg per day on a 4-weeks-on-2-weeks-off schedule or on 2weeks on 1 week off schedule. Safety was assessed regularly. Tumour measurements were scheduled per local practice. Results A total of 30 patients received sunitinib. Median treatment duration and follow-up were 8 and 13 months. Objective response rate was 34%. Median progression- freesurvival(PFS)andoverallsurvival(OS)were9monthsand11months.MedianPFS insubgroupsofinterest:aged60years(20%),8months;comparedto10monthsinage group <60 years. Eastern Cooperative Oncology Group performance status 0 or 1 (80%),10months;comparedto5.5monthsinpatientswithECOG2or3.LNmetastases (40%),11monthsand8monthsinpatientswithnoLNmetastasis.Themostcommon grade 3/4 treatment-related adverse events were fatigue (13%), hand and foot syndrome, and anemia (each7%), diarrhea and nausea (each 3%). Conclusions:Finalanalysisofthesunitinibreterospectivestudyprovidedagood opportunitytoevaluatethelong-termsideeffectsofatyrosinekinaseinhibitorused worldwide in mRCC. Efficacy and safety findings were consistent with previous results. Legal entity responsible for the study Ain Shams OncologyDepartment Funding Ain Shams Oncology Department Disclosure All authors have declared no conflicts ofinterest.